MATHEUS FREITAS CARDOSO DE AZEVEDO
Índice h a partir de 2011
5
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
- Fatal Presentation of Thrombotic Cutaneous Gangrene Associated With Acute Severe Colitis(2023) BARROS, Luisa Leite; PRADO, Rita de Cassia Parente; FERREIRA, Lucas Fortes Portela; AZEVEDO, Matheus Freitas Cardoso de; OBA, Jane; CARLOS, Alexandre de Souza; DAMIAO, Aderson Omar Mourao Cintra
- Anti-TNF Therapy in Elderly Patients With Inflammatory Bowel Disease in a Tuberculosis-Endemic Country(2023) BARROS, Luisa Leite; AZEVEDO, Matheus Freitas Cardoso de; CARLOS, Alexandre de Souza; LOPES, Paula De Azevedo; FUJITA, Andre Okuhara; BRITO, Daniela Sanches; KAMADA, Daniela Midori; PRADO, Rita de Cassia Parente; ANDRADE, Julia Carvalho De; OBA, Jane; DAMIAO, Aderson Omar Mourao Cintra
- Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial(2023) GARCIA, Karoline Soares; AZEVEDO, Matheus Freitas Cardoso de; CARLOS, Alexandre de Sousa; BARROS, Luisa Leite; OBA, Jane; SOBRADO JUNIOR, Carlos Walter; SIPAHI, Aytan Miranda; ALVES, Olivia Duarte de Castro; NAVARRO-RODRIGUEZ, Tomas; PARRA, Rogerio Serafim; CHEBLI, Julio Maria Fonseca; CHEBLI, Liliana Andrade; FLORES, Cristina; VIEIRA, Andrea; CEARA, Christianne Damasceno Arcelino do; QUEIROZ, Natalia Sousa Freitas; DAMIAO, Aderson Omar Mourao CintraTherapeutic drug monitoring (TDM) during induction therapy with anti-tumor necrosis factor drugs has emerged as a strategy to optimize response to these biologics and avoid undesired outcomes related to inadequate drug exposure. This study aimed to describe clinical, biological, and endoscopic remission rates at six months in Brazilian inflammatory bowel disease (IBD) patients following a proactive TDM algorithm guided by IFX trough levels (ITL) and antibodies to IFX (ATI) levels during induction, at week six. A total of 111 IBD patients were prospectively enrolled, excluding those previously exposed to the drug. ITL & GE; 10 & mu;g/mL was considered optimal. Patients with suboptimal ITL (<10 & mu;g/mL) were guided according to ATI levels. Those who presented ATI & LE; 200 ng/mL underwent dose intensification in the maintenance phase, and patients with ATI > 200 ng/mL discontinued IFX. In our study, proactive TDM was associated with persistence in the IFX rate at six months of 82.9%. At that time, rates of clinical, biological, and endoscopic remission in patients under IFX treatment were 80.2%, 73.9%, and 48.1%, respectively. Applying a simplified TDM-guided algorithm during induction seems feasible and can help improve patients' outcomes in clinical practice.
- Active tuberculosis in inflammatory bowel disease patients: a case-control study(2023) AZEVEDO, Matheus Freitas Cardoso de; BARROS, Luisa Leite; JUSTUS, Filipe Fernandes; OBA, Jane; GARCIA, Karoline Soares; MARTINS, Camilla de Almeida; CARLOS, Alexandre de Sousa; LEITE, Andre Zonetti Arruda; SIPAHI, Aytan Miranda; QUEIROZ, Natalia Sousa Freitas; DAMIAO, Aderson Omar Mourao CintraBackground/Aims:Anti-tumor necrosis factor (anti-TNF) drugs have been the mainstay therapy for moderate to severe inflammatory bowel disease (IBD) over the past 25 years. Nevertheless, these drugs are associated with serious opportunistic infections like tuberculosis (TB). Brazil is ranked among the 30 countries with the highest incidence of TB in the world. This study aimed at identifying risk factors for the development of active TB and describing clinical characteristics and outcomes in IBD patients followed at a tertiary referral center in Brazil. Methods:We conducted a retrospective, case-control study between January 2010 and December 2021. Active TB cases in IBD patients were randomly matched 1:3 to controls (IBD patients with no previous history of active TB) according to gender, age, and type of IBD. Design:This was a retrospective, case-control study. Results:A total of 38 (2.2%) cases of TB were identified from 1760 patients under regular follow-up at our outpatient clinics. Of the 152 patients included in the analysis (cases and controls), 96 (63.2%) were male, and 124 (81.6%) had Crohn's disease. Median age at TB diagnosis was 39.5 [interquartile range (IQR) 30.8-56.3]. Half of the active TB cases were disseminated (50%). Overall, 36 patients with TB (94.7%) were being treated with immunosuppressive medications. Of those, 31 (86.1%) were under anti-TNF drugs. Diagnosis of TB occurred at a median of 32 months after the first dose of anti-TNF (IQR 7-84). In multivariate analysis, IBD diagnosis older than 17 years and anti-TNF therapy were significantly associated with the development of TB (p < 0.05). After the TB treatment, 20 (52.7%) patients received anti-TNF therapy, and only one developed 'de novo' TB 10 years after the first infection. Conclusions:TB remains a significant health problem in IBD patients from endemic regions, especially those treated with anti-TNFs. In addition, age at IBD diagnosis (>17 years old) was also a risk factor for active TB. Most cases occur after long-term therapy, suggesting a new infection. The reintroduction of anti-TNFs agents after the anti-TB treatment seems safe. These data highlight the importance of TB screening and monitoring in IBD patients living in endemic areas.
- Risk of thrombosis and mortality in inflammatory bowel disease(2018) ANDRADE, Adriana R.; BARROS, Luisa L.; AZEVEDO, Matheus F. C.; CARLOS, Alexandre S.; DAMIAO, Aderson O. M. C.; SIPAHI, Aytan M.; LEITE, Andre Z. A.Objectives: Patients with inflammatory bowel disease have a higher risk of thrombosis, which is associated with a higher morbidity and mortality. Most data about VTE are related to hospitalized patients with active disease, but several cases happen in the outpatient setting, and are not covered by current prophylaxis recommendation. As the knowledge of VTE in outpatients is still poor, the aim of this study is to evaluate the risk, clinical data and mortality of thrombosis in patients followed in our center, comparing our findings with the current prophylaxis recommendation. Methods: The medical electronic chart of 1093 inflammatory bowel disease patients and their image exams were actively searched for words related to thrombosis, followed by charts reviewed to collect information about the event and data regarding clinical settings and thrombosis profile. Results: Overall, 654 Crohn's and 439 Colitis patients were included. Thrombosis prevalence was 5.1%, and mortality rate was higher in patients who had suffered thrombosis (10.71% vs. 1.45%, OR 8.0). Half of them developed thrombosis in the outpatient setting, 52% of these had disease activity, 17% had recent hospitalization, and 10% had previous thrombosis. In 27% of cases, diagnosis was done by routine image exams, with no clinical symptoms or previous history of thrombosis. None of them had used thromboprophylaxis. However, a great majority of patients who had thrombosis during hospitalization used heparin prophylaxis. Conclusion: Inflammatory bowel disease patients who develop thrombosis have an increased mortality risk. A significant proportion of the events happened in patients without a clear thromboprophylaxis recommendation or in those receiving heparin prophylaxis.
- Endoscopic activity, tissue factor and Crohn's disease: findings in clinical remission patients(2020) ANDRADE, Adriana Ribas; ROCHA, Tania Rubia Flores da; ORTIZ-AGOSTINHO, Carmen Lucia; NISHITOKUKADO, Ieda; CARLOS, Alexandre Sousa; AZEVEDO, Matheus Freitas Cardoso de; HASHIMOTO, Claudio Lioshi; DAMIAO, Aderson Omar Moura Cintra; CARRILHO, Flair Jose; D'AMICO, Elbio; SIPAHI, Aytan Miranda; LEITE, Andre Zonetti de ArrudaBackground: As Crohn's disease (CD) is associated with a high risk of thromboembolic events (TE), including patients with subclinical inflammation, we aim to evaluate the correlation between the impact of endoscopic activity (EA) in the coagulation profiling of CD patients while in clinical remission. Methods: From 164 consecutive CD patients included in clinical remission [Crohn's disease activity index (CDAI) < 150], 75 were in the EA group [Simplified Endoscopic Score for CD (SES-CD) > 7], 89 were in the endoscopic remission (ER) group (SES-CD <= 2), and 50 were included as healthy controls in the study. Blood samples were analyzed for tissue factor (TF), factor VIII (FVIII), thrombomodulin (TM), ADAMTS-13, von Willebrand factor (VWF), and endogenous thrombin potential (ETP), as well as collecting data regarding risk factors for TE and CD profile. Results: Mean plasma TF activity showed significantly higher levels in the EA group when compared with the ER and control groups (127 pMversus103 pMversus84 pM;p = 0.001), although the VWF:Ag (160%versus168%versus110%;p = 0.001), VWF/ADAMTS-13 (191versus219versus138;p = 0.003), FVIII (150%versus144%versus90%;p = 0.001) and TM (5.13 ng/mlversus4.91 ng/mLversus3.81 ng/ml;p < 0.001) were only increased in CD regardless of EA status when compared with controls. Lastly, ETP with and without TM remained the same in all three groups. Conclusions: CD patients in clinical remission with EA present endothelial lesion inducing TF exposure and subsequent coagulation cascade activation. Recommended thromboprophylaxis for EA outpatient subgroups will require additional investigation in order to be validated.
- Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients(2023) MARTINS, Camilla de Almeida; AZEVEDO, Matheus Freitas Cardoso de; CARLOS, Alexandre Sousa; DAMIAO, Aderson Omar Mourao Cintra; JR, Carlos Walter Sobrado; NAHAS, Sergio Carlos; QUEIROZ, Natalia Sousa FreitasBackground:Biological therapies have revolutionized the treatment of patients with inflammatory bowel disease (IBD). Infliximab (IFX) has been shown to be effective in inducing and maintaining remission in patients with Crohn's disease and ulcerative colitis. However, about one-third of the patients are primary non-responders, and up to half can lose response over time. Hence, it is important to assess which factors are related to treatment failure.Objectives:We aimed to identify factors predicting clinical and endoscopic remission with IFX treatment during maintenance therapy in a Brazilian IBD referral center.Design:We conducted a cross-sectional study to describe demographic, clinical, and IBD therapy-related characteristics of IBD patients treated with IFX for at least 6 months in a Brazilian referral center. Subsequently, we evaluated factors associated with clinical and endoscopic remission (primary and secondary outcomes, respectively).Methods:We used descriptive statistics to summarize the essential demographic and clinical characteristics of the population. The association of sociodemographic and clinical variables with outcomes was analyzed using multivariable logistic regression.Results:A total of 131 IBD patients (the mean age 41.7 years) were enrolled in this study. Clinical and endoscopic remission were observed in 79.4% and 58.2% of the patients, respectively. In the multivariable analysis, IFX therapy duration and higher albumin levels increased the likelihood of clinical remission, while previous surgery decreased its chance. Prior use of adalimumab and higher C-reactive protein levels reduced the likelihood of endoscopic remission.Conclusion:In summary, this study has enhanced our understanding of the predictive factors of treatment response to IFX in a well-characterized Brazilian IBD population.Trial registration:4.254.501 and 2.903.748.
- An Unusual Presentation of Tuberculosis in a Crohn's Disease Patient Treated With Anti-TNF(2022) BARROS, L. L.; CARLOS, A. de Sousa; AZEVEDO, M. F. C. D.In view of the increase in the therapeutic arsenal available for the treatment of inflammatory bowel disease in recent years, concerns about safety and side effects of immunosuppressive therapies have been increasingly common in clinical practice. The combination of thiopurines and anti-tumor necrosis factor agents exposes patients to greater risks of serious and opportunistic infection such as tuberculosis (TB). Here we report a case of a 38-year-old female with an 8-year history of a fistulizing ileocolonic and perianal Crohn's disease that developed TB on the tongue and disseminated during treatment with adalimumab and azathioprine. TB remains a global public health problem characterized by high morbidity and mortality worldwide. The reported case draws attention to an extremely unusual presentation of TB involving the tongue. TB should be included in the differential diagnosis of oral lesions in patients with inflammatory bowel disease, especially in endemic areas.